Item
8.01 Other Events.
The
following is a list of intellectual property (“IP”) controlled by either Regen Biopharma, Inc. ( the “Company”)
or KCL Therapeutics (“KCL”). KCL is a wholly owned subsidiary of the Company.
IP
which has been granted patent protection by the United States Patent and Trademark Office (“USPTO”)
GENE
SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS)
Provides
methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory
of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells,
which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer
therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.
Patent
No: 8263571
METHODS
AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION
Means,
methods, and compositions of matter useful for generation of cancer inhibitory effector cells producing interleukin-17 (IL-17).
In one embodiment a cellular population is obtained, said cellular population is exposed to agents capable of inhibiting NR2F6,
whereby said inhibition of NR2F6 results in upregulation of IL-17 production, said upregulation of IL-17 production associated
with acquisition of anti-tumor activity.
Patent
No : 11,053,503
METHODS
OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND
Compositions
of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor
NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound.
Patent
No: 10,088,485
MODULATION
OF NR2F6 AND METHODS AND USES THEREOF
The
application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a
NR2F6 modulator
Patent
No: 9091696
IP
for which a Notice of Allowance has been granted. A Notice of Allowance is notification by the USPTO to the applicant that the
USPTO intends to issue a patent
ANTIGEN
SPECIFIC MRNA CELLULAR CANCER VACCINES
Antigen
specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding
said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin.
By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated
intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments
likelihood of successful induction of immunity.
Application
Number: 15/162,370
IP
for which Patent Protection has expired due to non payment of fees for which revival is in process:
METHOD
OF CANCER TREATMENT USING SIRNA SILENCING
Comprises
administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule.
The invention also provides siRNA constructs and compositions.
Patent
No: 8389708
IP
for which a Notice of Allowance was granted but classified as abandoned by the USPTO. Revival in progress.
UNIVERSAL
DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS
Compositions
of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In
one embodiment the invention provides the use of NR2F6 silencing or gene editing in cord blood cells possessing anti-tumor activity
in order to induce potentiated killer cells suitable for therapeutic use. In one embodiment said allogeneic cord blood killer
cells are administered to initiate a cascade of antitumor immune responses, with initially responses mediated by allogeneic killer
cells, and followed by endogenous immune responses.
Application
Number: 15/494,358
Active
Patent Applications:
ENHANCED
DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL;
Application
Number 17035955.
REDUCTION
OF POST-SURGERY CANCER METASTASIS BY COMBINATION OF CANNABIDIOL AND NR2F6 INHIBITION.
Application
Number 17037284
SUPPRESSION
OF PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF NR2F6
Application
Number 17087386
STIMULATION
OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY
Application
Number 17010720
SMALL
MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS
Application
Number 15820324
SMALL
MOLECULE MODULATORS OF NR2F6 ACTIVITY.
Application
Number 15364111
Patent
issued to Zander Therapeutics, Inc. derived from intellectual property licensed by Zander Therapeutics Inc. from KCL.
CANINE
AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES
Compositions
of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention
provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in
vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T
cells possessing tumor cytotoxic activity induced by stimulation of NKG2D.
Patent
Number: 10,030,227